AI
AXSM icon

Axiom Investors’s Axsome Therapeutics AXSM Stock Holding History

Axiom Investors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.54M Sell
22,631
-33,898
-60% -$7.35M 0.05% 109
2026
Q1 		$9.55M Sell
56,529
-6,861
-11% -$1.19M 0.11% 79
2025
Q4 		$11.6M Buy
63,390
+14,137
+29% +$1.97M 0.1% 78
2025
Q3 		$5.98M Buy
49,253
+22,147
+82% +$2.49M 0.04% 94
2025
Q2 		$2.83M Buy
27,106
+799
+3% +$84.6K 0.02% 117
2025
Q1 		$3.07M Buy
+26,307
New +$3M 0.03% 113

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Axiom Investors's AXSM Position: Q2 2026 in Review

Axiom Investors reduced its Axsome Therapeutics (AXSM) stake by 60% in Q2 2026, selling an estimated $7.35M and leaving 22,631 shares worth $5.54M. The position accounts for 0.05% of the portfolio, ranked #109.

Axiom Investors first reported a position in AXSM in Q1 2025 and has held it in 6 quarters since. The position peaked at $11.6M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Axiom Investors held 22,631 shares of Axsome Therapeutics worth $5.54M as of Q2 2026.
  • Axiom Investors sold 33,898 Axsome Therapeutics shares in Q2 2026, an estimated $7.35M.
  • Axsome Therapeutics made up 0.05% of Axiom Investors's portfolio in Q2 2026, its #109 holding.
  • Axiom Investors first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Axiom Investors's Axsome Therapeutics position peaked at $11.6M in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Axiom Investors's 13F filing for Q2 2026, filed 12 Aug 2026.